AnaptysBio, Inc. (ANAB)
Last updated: 2026-10-24 13:36:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
AnaptysBio, Inc. (ANAB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $48.74, with a market capitalization of $1.44B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $30.27 to $73.30. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.44B | |
$48.19 | |
$134.00 | |
$10.00 | |
$48.10 | |
378.73K | |
505.15K | |
-- | |
$73.30 | |
$30.27 | |
-- | |
-- |
AnaptysBio, Inc. (ANAB) Latest Closing Stock Price
AnaptysBio, Inc. (ANAB) last closed at $48.10 as of 2026-10-23 23:31:00, unchanged from the previous close of $48.10.
During the latest regular trading session, ANAB traded between $10.00 and $134.00, with a volume of 378.73K shares. The closing price was near the lower end and near the middle of its 52-week range.
AnaptysBio, Inc. (ANAB) 7-Day Stock Price Change
Over the past seven days, AnaptysBio, Inc. (ANAB) moved from $48.71 to $48.74, representing a gain of 0.06% ($0.03).
The stock traded between $44.02 and $51.86 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 555.99 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
ANAB 52-Week Price Position
Position in Range: 42.9%
ANAB is currently trading at $48.74, placing it 42.9% of the way from its 52-week low of $30.27 to its 52-week high of $73.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is AnaptysBio, Inc. (ANAB)?
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
AnaptysBio, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 104 |
| Exchange | NASDAQ |
| Company Website |
How to Buy AnaptysBio, Inc. (ANAB) Stock on MEXC
Eligible investors can buy real shares of AnaptysBio, Inc. (ANAB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is AnaptysBio, Inc. (ANAB) stock price today?
2.Is ANAB stock going up or down today?
3.What is ANAB pre-market price?
4.What is ANAB after-hours price?
5.Is ANAB stock trading now?
6.Where does ANAB sit relative to its 52-week high and low?
7.What sector is AnaptysBio, Inc. in?
8.What is AnaptysBio, Inc.'s market capitalization and where is it listed?
9.How is ANAB valued in terms of P/E ratio and EPS?
10.Does AnaptysBio, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ANAB Stock Calculator
Estimate the value between ANAB shares and USD.
ANAB Shares to USD
1.00 ANAB shares = 48.737 USD
Calculations are estimates based on the latest available price and are for reference only.


